BRISTOL MYERS SQUIBB
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis
- First Posted Date
- 2019-02-05
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 9
- Registration Number
- NCT03831438
- Locations
- ๐บ๐ธ
UCLA, Los Angeles, California, United States
๐บ๐ธHospital of Special Surgery, New York, New York, United States
๐บ๐ธUniversity of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
A Study of Participants in Australia Who Have Non-small Cell Lung Cancer Being Treated With Nivolumab
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2019-01-15
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 503
- Registration Number
- NCT03804554
- Locations
- ๐ฆ๐บ
Local Institution, Heidelburg, Victoria, Australia
A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 12
- Registration Number
- NCT03792750
- Locations
- ๐จ๐ณ
Local Institution, Hangzhou, Zhejiang, China
A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed
Active, not recruiting
- Conditions
- Melanoma
- First Posted Date
- 2018-12-11
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 152
- Registration Number
- NCT03771859
- Locations
- ๐ฑ๐บ
Local Institution, Luxembourg, Luxembourg
An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
Phase 2
Withdrawn
- Conditions
- Circulating Tumor DNANon-Small Cell Lung CancerNon-Small-Cell Lung Carcinoma
- Interventions
- Biological: NivolumabOther: Observation
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT03770299
A Study of Juvenile Idiopathic Arthritis Patients Given Abatacept and the Number of Infections or Malignancies That Occur
Completed
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2020-03-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 264
- Registration Number
- NCT03769558
- Locations
- ๐บ๐ธ
Local Institution, Princeton, New Jersey, United States
A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
Phase 2
Completed
- Conditions
- Acute Ischemic StrokeTransient Ischemic Attack (TIA)
- Interventions
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 2366
- Registration Number
- NCT03766581
- Locations
- ๐บ๐ธ
Temple University Hospital, Philadelphia, Pennsylvania, United States
๐บ๐ธLocal Institution - 0019, York, Pennsylvania, United States
๐บ๐ธNeurology Consultants of Dallas, PA, Dallas, Texas, United States
Evaluation of Safety and Effectiveness on Oral Anticoagulants
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 12354
- Registration Number
- NCT03765242
- Locations
- ๐ฏ๐ต
Local Institution, Minato-ku, Tokyo, Japan
A Taste Assessment of BMS-986165 in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- Drug: Active Pharmaceutical Ingredient
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2019-10-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 9
- Registration Number
- NCT03751228
- Locations
- ๐บ๐ธ
Senopsys, Woburn, Massachusetts, United States
An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Cancer
- Interventions
- Biological: NKTR-214Biological: Nivolumab
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 3
- Registration Number
- NCT03745807
- Locations
- ๐ฏ๐ต
Local Institution, Chuo-ku, Tokyo, Japan
ยฉ Copyright 2025. All Rights Reserved by MedPath